- +62 21 29189160 (ext. 201912)
- manajer.riset.fkui1@gmail.com
- Senin-Jum'at 8.00 s/d 16.00 WIB
Publikasi Scopus 2023 per tanggal 28 Februari 2023 (121 artikel)
Publikasi Scopus 2023 per tanggal 28 Februari 2023 (121 artikel)
Complete blood count derived inflammatory biomarkers and the level of anti-SARS-CoV-2 NAb and S-RBD IgG among cancer survivors receiving COVID-19 vaccines
2023
Electronic Journal of General Medicine
20
2
em456
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147743238&doi=10.29333%2fejgm%2f12851&partnerID=40&md5=d53d07be03f53203b2f1a6b7fc796378
Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital-Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Clinical Pathology, Yarsi University, Jakarta, Indonesia; Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital-Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
Background: In the era of coronavirus disease 2019 (COVID-19), it is mandatory to identify vulnerable people with cancers as they have impaired immune system that can lead to high mortality. This study analyzes the complete blood count (CBC) derived inflammatory biomarkers and the level of anti-SARS-CoV-2 neutralizing antibody (NAb) and spike protein’s receptor-binding domain immunoglobulin G (S-RBD IgG) among cancer survivors. Methods: A cross-sectional study was conducted in patients with either solid or hematological cancers who had received two-doses of COVID-19 vaccinations within six months. Results: From 119 subjects, the COVID-19 vaccines demonstrated laboratory efficacy (median NAb=129.03 AU/mL; median S-RBD IgG=270.53 AU/mL). The seropositive conversion of NAb reached 94.1% and S-RBD IgG reached 93.3%. Additionally, the S-RBD IgG had very weak correlation with absolute monocyte count (R=-0.185; pvalue=0.044). The NAb also had very weak correlation with leukocyte (Kendall’s tau-b (τb)=-0.147; p-value=0.019), absolute neutrophil count (τb=-0.126; p-value=0.044), absolute eosinophil count (τb=-0.132; p-value=0.034). Conclusion: The seropositivity rate of anti-SARS-CoV-2 NAb and S-RBD IgG were significantly high. However, the CBC derived inflammatory biomarkers had poor correlation with anti-SARS-CoV-2 NAb and S-RBD IgG. Thus, antiSARS-CoV-2 NAb and S-RBD IgG are currently the only reliable markers for measuring the COVID-19 vaccine efficacy which should be widely accessible. © 2023 by Author/s and Licensed by Modestum. All rights reserved.
bbibp corv; biological marker; chadox1; coronavac; covilo; elasomeran; immunoglobulin G; neutralizing antibody; SARS-CoV-2 antibody; SARS-CoV-2 vaccine; tozinameran; vaxzevria; virus spike protein; absolute eosinophil count; absolute lymphocyte count; absolute monocyte count; absolute neutrophil count; adult; antibody titer; Article; basophil to lymphocyte ratio; blood cell count; cancer survivor; chemiluminescence immunoassay; cross-sectional study; eosinophil to lymphocyte ratio; female; hematologic malignancy; human; leukocyte count; major clinical study; male; monocyte lymphocyte ratio; multicenter study; neutrophil lymphocyte ratio; platelet count; platelet lymphocyte ratio; protein domain; questionnaire; receptor binding; solid malignant neoplasm; systemic immune-inflammation index;
Author contributions: AR & AI: conception & design; CI, LS, WR, & NAM: interpreted the results; AML, FP, & RC: performed the statistical analysis; & DP, BBR, RB, & SJ: drafted the manuscript; and Rachman A supervised the study. All authors read and approved the final manuscript. All authors have agreed with the results and conclusions. Funding: This study was funded by Dr. Cipto Mangunkusumo Natio
Modestum LTD
25163507
Article
Q3
297
14867
© 2024 Riset & Pengabdian Masyarakat. All Rights Reserved.